EC Approves Sanofi’s Meningococcal Meningitis Vaccine

News
Article

The EC’s approval comes after positive results from seven Phase II and III randomized, active-controlled, multi-center studies.

Sanofi announced on Nov. 23, 2020 that the European Commission (EC) approved MenQuadfi (meningococcal [groups A, C, Y, W] conjugate vaccine) for immunization against meningococcal meningitis, the inflammation of the brain and spinal cord caused by a viral infection, in patients from the age of 12 months and older.

The EC’s approval comes after positive results from seven Phase II and III randomized, active-controlled, multi-center studies, a Sanofi press release said. Immunogenicity and safety of the vaccine were assessed in 6300 individuals who received a single dose of MenQuadfi, which showed a good safety profile and induced a high immune response against all four Neisseria meningitidis serogroups.

“Meningococcal meningitis can take one’s life in as little as one day and leave survivors with severe permanent disabilities. In Europe, there were more than 3000 cases of Invasive Meningococcal Disease in 2018, half of them caused by serogroups C, W, and Y,” said Thomas Triomphe, head of Sanofi Pasteur, in the press release. “One case is one too many. It is our ambition to make this vaccine available worldwide to further expand protection to as many people as possible. The European Commission’s approval of MenQuadfi takes us one step closer to achieving this goal.”

Source: Sanofi

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes